BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 35608039)

  • 21. Real-World Evaluation of Direct and Indirect Economic Burden Among Endometriosis Patients in the United States.
    Soliman AM; Surrey E; Bonafede M; Nelson JK; Castelli-Haley J
    Adv Ther; 2018 Mar; 35(3):408-423. PubMed ID: 29450864
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Healthcare resource utilization and costs 2 years pre- and post-lumbar spine surgery for stenosis: a national claims cohort study of 22,182 cases.
    Koltsov JCB; Sambare TD; Alamin TF; Wood KB; Cheng I; Hu SS
    Spine J; 2022 Jun; 22(6):965-974. PubMed ID: 35123048
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterizing the real-world economic burden of metastatic castration-sensitive prostate cancer in the United States.
    Kaye DR; Khilfeh I; Muser E; Morrison L; Kinkead F; Lefebvre P; Pilon D; George D
    J Med Econ; 2024; 27(1):381-391. PubMed ID: 38420699
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Healthcare resource utilization and costs for hip dislocation following primary total hip arthroplasty in the medicare population.
    Mantel J; Chitnis AS; Ruppenkamp J; Holy CE; Daccach J
    J Med Econ; 2021; 24(1):10-18. PubMed ID: 33267624
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of Proteinuria and Kidney Function Decline on Health Care Costs and Resource Utilization in Adults With IgA Nephropathy in the United States: A Retrospective Analysis.
    Lerma EV; Bensink ME; Thakker KM; Lieblich R; Bunke M; Rava A; Wang K; Murphy MV; Oliveri D; Amari DT; Cork DMW; Velez JCQ
    Kidney Med; 2023 Sep; 5(9):100693. PubMed ID: 37637862
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economic burden to commercial payers of young adults with schizophrenia in Colorado.
    Pesa J; Patel C; Rotter D; Papademetriou E; Potluri R; Benson C
    J Med Econ; 2021; 24(1):1194-1203. PubMed ID: 34666605
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Health resource utilization and costs of care for adult patients with relapsed or refractory mantle cell lymphoma in the United States: a retrospective claims analysis.
    Ito D; Feng C; Fu C; Kim C; Wu J; Epstein J; Snider JT; DuVall AS
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):773-787. PubMed ID: 37278284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and economic characterization of mild, moderate, and severe systemic lupus erythematosus: Real-world observation across payer channels in the United States.
    Wu SS; Perry A; Tkacz J; Bryant G
    J Manag Care Spec Pharm; 2023 Sep; 29(9):1010-1020. PubMed ID: 37610115
    [No Abstract]   [Full Text] [Related]  

  • 29. The Economic Burden of Eosinophilic Gastritis and Eosinophilic Enteritis in the United States.
    Woolley M; Cook EE; Mu F; Betts KA; Billmyer E; Yim E; Chen J; Wu EQ
    Adv Ther; 2022 Aug; 39(8):3547-3559. PubMed ID: 35689161
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Retrospective database analysis of healthcare resource utilization and costs in patients who develop post-transplant lymphoproliferative disease within the first year following allogeneic hematopoietic stem cell transplants.
    Watson C; Xu H; Princic N; Sruti I; Barlev A
    J Med Econ; 2020 Oct; 23(10):1159-1167. PubMed ID: 32643493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Excess healthcare costs in patients with autosomal dominant polycystic kidney disease by renal dysfunction stage.
    Gagnon-Sanschagrin P; Liang Y; Sanon M; Oberdhan D; Guérin A; Cloutier M
    J Med Econ; 2021; 24(1):193-201. PubMed ID: 33464936
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Healthcare resource utilization and costs in the 12 months following hospitalization for respiratory syncytial virus or unspecified bronchiolitis among infants.
    Ledbetter J; Brannman L; Wade SW; Gonzales T; Kong AM
    J Med Econ; 2020 Feb; 23(2):139-147. PubMed ID: 31432723
    [No Abstract]   [Full Text] [Related]  

  • 33. Direct economic burden of high-risk and metastatic melanoma in the elderly: evidence from the SEER-Medicare linked database.
    Davis KL; Mitra D; Kotapati S; Ibrahim R; Wolchok JD
    Appl Health Econ Health Policy; 2009; 7(1):31-41. PubMed ID: 19558193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Health care resource use, short-term disability days, and costs associated with states of persistence on antidepressant lines of therapy.
    Pilon D; Karkare S; Zhdanava M; Sheehan JJ; Côté-Sergent A; Shah A; Lopena OJ; Lefebvre P; Joshi K; Citrome L
    J Med Econ; 2021; 24(1):1299-1308. PubMed ID: 34763603
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health Care Resource Use, Costs, and Diagnosis Patterns in Patients With Schizophrenia and Bipolar Disorder: Real-world Evidence From US Claims Databases.
    Broder MS; Greene M; Chang E; Hartry A; Touya M; Munday J; Yan T
    Clin Ther; 2018 Oct; 40(10):1670-1682. PubMed ID: 30193748
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Matched cohort study of healthcare resource utilization and costs in young children of mothers with postpartum depression in the United States.
    Moore Simas TA; Huang MY; Packnett ER; Zimmerman NM; Moynihan M; Eldar-Lissai A
    J Med Econ; 2020 Feb; 23(2):174-183. PubMed ID: 31597499
    [No Abstract]   [Full Text] [Related]  

  • 37. Healthcare resource utilization and costs associated with patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive NSCLC in the United States.
    Samuelsen C; Lim J; Golembesky A; Shrestha S; Wang L; Griebsch I
    J Med Econ; 2020 Jan; 23(1):48-53. PubMed ID: 31314630
    [No Abstract]   [Full Text] [Related]  

  • 38. Economic burden of skeletal-related events in patients with multiple myeloma: analysis of US commercial claims database.
    Bhowmik D; Hines DM; Intorcia M; Wade RL
    J Med Econ; 2018 Jun; 21(6):622-628. PubMed ID: 29571273
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Healthcare Costs in Men with Metastatic Castration-Resistant Prostate Cancer: An Analysis of US Medicare Fee-For-Service Claims.
    Freedland SJ; Davis MR; Epstein AJ; Arondekar B; Ivanova JI
    Adv Ther; 2023 Oct; 40(10):4480-4492. PubMed ID: 37531024
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Healthcare costs of NVAF patients treated with rivaroxaban and apixaban in the US.
    Milentijevic D; Germain G; Laliberté F; Bookhart BK; MacKnight SD; Tsang J; Lefebvre P
    J Med Econ; 2020 Nov; 23(11):1365-1374. PubMed ID: 32897766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.